NCT07573826Not yet recruiting
Effect of Pursed-Lip Breathing With Different I:E Ratios on Respiratory Outcomes in COPD Patients
Effectiveness of Different Inspiratory-Expiratory Ratios (1:3, 1:4, and 1:5) in Pursed-Lip Breathing on Respiratory Rate, Oxygen Saturation, and Dyspnea in Patients With Chronic Obstructive Pulmonary Disease: A Quasi-Experimental Study
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate whether different inspiratory-expiratory (I:E) ratios in the pursed-lip breathing (PLB) technique can improve respiratory outcomes in patients with stable Chronic Obstructive Pulmonary Disease (COPD) aged 40 years and older. The primary purpose is to determine whether a specific breathing intervention can improve respiratory function. The main questions it aims to answer are: Does PLB with different I:E ratios (1:3, 1:4, and 1:5) reduce respiratory rate in COPD patients? Does PLB with different I:E ratios improve oxygen saturation and reduce dyspnea severity? Researchers will compare PLB with I:E ratios of 1:3, 1:4, and 1:5 and a control group receiving standard care to see if different ratios produce different effects on respiratory rate, oxygen saturation, and dyspnea levels. Participants will: Perform pursed-lip breathing using assigned I:E ratios (1:3, 1:4, or 1:5) for 10 minutes Be assigned to either an intervention group or a control group (standard care) Have their respiratory rate measured before and after the intervention Have their oxygen saturation measured using a pulse oximeter Report their dyspnea level using the Modified Borg Scale before and after the intervention
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 122 (estimated)
- First submitted
- 30 Apr 2026
- Start date
- 4 May 2026
- Primary completion date
- 7 Aug 2026
- Lead sponsor
- Scholastica Fina Aryu Puspasari
- Diseases
- COPD
- NCT number
- NCT07573826
What you commit to
- Study type: Interventional
- Planned participants: 122
- From 4 May 2026 to the primary completion date, 7 Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Cognitive impairment or decreased consciousness
- Severe cardiovascular disease (heart failure, coronary artery disease, pulmonary hypertension)
- Acute respiratory infection (e.g., pneumonia)
- Neuromuscular disorders affecting respiratory muscles
Other
- Asthma-COPD overlap (ACO)
Who the study is looking for
- Diagnosed with stable COPD
- Age ≥ 40 years
- Able to follow breathing instructions
- Willing to participate and provide informed consent
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.